BANB N Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 1,741.42 |
| 52 Week High | CHF 1,741.42 |
| 52 Week Low | CHF 1,656.65 |
| Beta | 0.77 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 4.34% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| BANB N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 4.3% | 0% | 0% |
Return vs Industry: BANB N exceeded the MX Life Sciences industry which returned -14.6% over the past year.
Return vs Market: BANB N matched the MX Market which returned 3.7% over the past year.
Price Volatility
| BANB N volatility | |
|---|---|
| BANB N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BANB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BANB N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 1,776 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANB N fundamental statistics | |
|---|---|
| Market cap | Mex$136.86b |
| Earnings (TTM) | Mex$1.94b |
| Revenue (TTM) | Mex$10.27b |
70.4x
P/E Ratio13.3x
P/S RatioIs BANB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANB N income statement (TTM) | |
|---|---|
| Revenue | CHF 531.74m |
| Cost of Revenue | CHF 360.46m |
| Gross Profit | CHF 171.28m |
| Other Expenses | CHF 70.60m |
| Earnings | CHF 100.68m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Jul 27, 2023
| Earnings per share (EPS) | 1.34 |
| Gross Margin | 32.21% |
| Net Profit Margin | 18.93% |
| Debt/Equity Ratio | 0% |
How did BANB N perform over the long term?
See historical performance and comparison